Benign Prostatic Hyperplasia Surgical Devices Market Insights
Benign prostate hyperplasia (BPH) refers to the non-cancerous enlargement of prostate. The treatment option depends on various factors such as age of the patient, prostate gland size, and severity of the disease. According to an article published in Urologic Clinic of North America, 2016, BPH is a common problem that affects over 20% of men in the U.S., which is around 15 million men. The treatment option includes medication, surgery such as open prostatectomy, transurethral resection of the prostate (TURP), and minimally invasive therapies such as transurethral needle ablation (TUNA) and minimally invasive therapies such as laser therapy, radiofrequency ablation, implants and others.
Increasing demand for minimally invasive therapies is expected to boost growth of the benign prostatic hyperplasia surgical devices market
Minimally invasive surgeries have gained traction in the recent past, owing to various advantages such as significant reduction in postoperative pain, decreased recovery time, reduced hospital stays, lesser surgical scars, laparoscopic incisions being safer than open incisions, equivalent or better safety, and efficacy in abdominal and general surgeries as compared to open surgeries, and these surgeries may be less expensive than open surgeries. Moreover, these therapies offer one-time permanent solution rather than long-time dependent on medications. Currently, more than 60% and 20% of patients suffering from benign prostatic hyperplasia is on drugs and under observation. The minimally invasive therapies are focusing on these groups particularly and have also witnessed some success in attracting such customers.
For instance, implant, manufactured by NeoTract, Inc., (now acquired by Teleflex Incorporated), which entered U.S. market in 2013-14 saw exponential revenue growth in last 2 years, 2015 and 2016. In first two quarters of 2017 alone, the revenue generated crossed the revenue generated in last year (i.e. 2016) and is expected to perform similar in remaining two quarters of the year. By 2025, the revenue generated from implants may occupy nearly 40% share of the total benign prostatic hyperplasia surgical devices market, which is huge considering the recent introduction of products in market. There are other novel therapies, such as prostate artery embolization developed by Merit Medical Systems, Inc. and aquablation device developed by Procept BioRobotics, which demonstrated impressive therapeutic results in the clinical trials. These products with improved efficacy is expected to significantly enhance the adoption rate, in turn boosting the growth of the market.
The global benign prostatic hyperplasia surgical devices market was valued at US$ 375.9 million in 2016 and is expected to witness a robust CAGR of 7.5% over the forecast period (2017 – 2025).
Figure 1. Global Benign Prostatic Hyperplasia Surgical Devices Market (US$ Mn), by Region, 2016
Increasing geriatric population is expected to drive the growth of benign prostatic hyperplasia surgical devices market
Benign prostatic hyperplasia is the most common prostate problem in men aged 50 years and above and the occurrence of the same tends to increase with age. According to the U.S. Census Bureau, 2015, among 7.3 billion people worldwide, an estimated 617.1 million people were aged 65 years and older and the number of geriatric population is expected to increase above 60% by year 2030 indicating the potential population base associated with lower urinary tract symptoms (LUTS) resulting due to benign prostatic hyperplasia. According to the Population Reference Bureau, numbers of American aged 65 years and above are expected to reach up to 98 million by 2060, more than double from 2014 and will constitute about one-fourth of the total population. This increasing aging population presents immense market opportunity for companies, specifically start-ups working on novel therapies such as ProVerum Limited, ProArc Medical and Zenflow, and Others.
Some major players operating in the benign prostatic hyperplasia surgical devices market are Olympus Corporation, Boston Scientific Corporation, Medifocus Inc., KARL STORZ SE & Co. KG, NxThera, Inc., ProArc Medical, Lisa Laser Products OHG, and Richard Wolf Gmbh.
Benign prostatic hyperplasia (BPH) is a medical condition, which is characterized by non-cancerous enlargement of prostate and it generally affects men aged more than 50 years. According to the study published in The Lancet in 2015, more than 100 million people were suffering from benign prostatic hyperplasia (BPH) globally. Drugs such as Alpha- blockers and 5α-Reductase inhibitors (5ARIs), surgery such as transurethral resection of the prostate (TURP), and minimally invasive surgeries such as implants, radiofrequency ablation, and lasers are the primary treatment options available for the disease. As surgery and minimally invasive therapy offers permanent solution, the benign prostatic surgical devices market is expected to grow significantly during the forecast period.
Increasing demand for minimally invasive therapy such as implants, prostatic stents and laser therapy are expected to be primary driving force for this market. Although implant has entered very late in benign prostatic hyperplasia market, its demand is increasing. NeoTract, Inc. received the approval for first implant for benign prostatic hyperplasia in 2010 and 2013 in Europe and U.S. respectively. This huge transaction value underlines the market opportunity for such products in developed economies such as the U.S. and European economies in short-term period and globally in long-term period. Other novel treatment options such as prostatic artery embolization (PAE) has also gained traction in recent years and its application for benign prostatic hyperplasia treatment is expected to get streamlined in near future. The introduction of novel treatments options such as PAE is expected to lead to further growth in the market. Moreover, increasing aging population, which is more prone to the disease is expected to support the growth of this market. According to Population Reference Bureau, the number of American people aged 65 years and above is expected to more than double from 46 million in 2014 to 98 million by 2060.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 27 market data tables and 22 figures on "Benign Prostatic Hyperplasia Surgical Devices Market - Global forecast to 2025”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.